Source: CureToday articles
Dr. Alexander Chehrazi-Raffle discusses findings from the phase 3 TiNivo-2 trial, designed to evaluate treatment with Fotivda in patients with metastatic renal cell carcinoma.
Recent Content
- Breaking Financial Barriers: Pharmacists as Value-Driven Health Care Providers
- A Unicorn Among Us
- Understanding Supportive Care Needs in Younger Women With Cancer
- ASCO 2025: Camizestrant With CDK4/6 Inhibitor Improves PFS in Patients With HR+/HER2- Advanced Breast Cancer
- Diving Into Every FDA Drug Approval for Cancer Care During May 2025
- To Combat Medication Errors, Proper Pharmacy Inventory Counts Are Essential
- Targeted Screening Tools Can Increase Pneumococcal Vaccine Uptake in Health-System Retail Pharmacies
- Study Finds Vitamin D3 Supplementation Reduces Telomere Attrition
- Vadadustat and Darbepoetin Alfa Show Similar Safety, Efficacy in Patients With NDD-CKD and DD-CKD
- Being in the Present Moment With Multiple Myeloma